Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 57 clinical trials
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

myeloma remains an incurable disease, future improved OS is therefore reliant on the expansion of salvage options for patients with RRMM. Carfilzomib (formerly PR-171) is a tetrapeptide epoxyketone

  • 22 views
  • 21 Jan, 2021
  • 1 location
Elotuzumab in Combination With Carfilzomib Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients. One phase III trial in MM patients with one to three prior lines of therapy compared elotuzumab-Rd with standard Rd. …

  • 8 views
  • 03 Mar, 2021
  • 58 locations
Study of Early Relapsed Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

  • 0 views
  • 26 Aug, 2021
  • 83 locations
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in

  • 18 views
  • 03 Sep, 2021
  • 222 locations
Dexamethasone Carfilzomib & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

This phase I trial studies the side effects and best dose of wild-type reovirus (pelareorep) when given together with dexamethasone, carfilzomib, and nivolumab in treating patients with multiple

hysterectomy
platelet count
oophorectomy
immunoglobulin
carfilzomib
  • 21 views
  • 28 Jan, 2021
  • 2 locations
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

To characterize safety associated with the use of Kyprolis under the locally approved label.

  • 0 views
  • 26 Aug, 2021
  • 26 locations
Selinexor Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does

neutrophil count
plasmacytoma
platelet count
growth factor
progressive disease
  • 5 views
  • 27 Jan, 2021
  • 3 locations
Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation

The clinical trial is a Phase II open label, single-arm pilot study to evaluate the safety and efficacy of combination therapy with carfilzomib, plasma exchange and intravenous immunoglobulins

  • 2 views
  • 24 Jan, 2021
  • 1 location
Treatment of Relapsed/Refractory Multiple Myeloma With t 11;14 Translocation Using BGB-11417 With Dexamethasone; Also Using BGB-11417 in Combination With Dexamethasone and Carfilzomib.

Study consists of two parts, a part 1 dose escalation and a part 2 (cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts)

  • 0 views
  • 26 Sep, 2021
  • 2 locations
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

" PETHEMA arm for fit elderly VMP x 9 + Rd x 9 (arm 1, control arm), a KRd regimen (arm 2a) (18 cycles) or a Carfilzomib-lenalidomida-dexametasona regimen combined with DARATUMUMAB (arm 2b) (18 cycles

  • 12 views
  • 24 Mar, 2021
  • 89 locations